These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 21154128)

  • 1. STA-9090, a small-molecule Hsp90 inhibitor for the potential treatment of cancer.
    Wang Y; Trepel JB; Neckers LM; Giaccone G
    Curr Opin Investig Drugs; 2010 Dec; 11(12):1466-76. PubMed ID: 21154128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent updates on the development of ganetespib as a Hsp90 inhibitor.
    Choi HK; Lee K
    Arch Pharm Res; 2012 Nov; 35(11):1855-9. PubMed ID: 23212626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ganetespib and HSP90: translating preclinical hypotheses into clinical promise.
    Proia DA; Bates RC
    Cancer Res; 2014 Mar; 74(5):1294-300. PubMed ID: 24556722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.
    Powers MV; Workman P
    Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S125-35. PubMed ID: 17259553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel, small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitor induced apoptosis in HCT116 colon carcinoma cells.
    Massey AJ; Williamson DS; Browne H; Murray JB; Dokurno P; Shaw T; Macias AT; Daniels Z; Geoffroy S; Dopson M; Lavan P; Matassova N; Francis GL; Graham CJ; Parsons R; Wang Y; Padfield A; Comer M; Drysdale MJ; Wood M
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):535-45. PubMed ID: 20012863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
    Schwock J; Pham NA; Cao MP; Hedley DW
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy.
    Bao R; Lai CJ; Qu H; Wang D; Yin L; Zifcak B; Atoyan R; Wang J; Samson M; Forrester J; DellaRocca S; Xu GX; Tao X; Zhai HX; Cai X; Qian C
    Clin Cancer Res; 2009 Jun; 15(12):4046-57. PubMed ID: 19509149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy.
    Ying W; Du Z; Sun L; Foley KP; Proia DA; Blackman RK; Zhou D; Inoue T; Tatsuta N; Sang J; Ye S; Acquaviva J; Ogawa LS; Wada Y; Barsoum J; Koya K
    Mol Cancer Ther; 2012 Feb; 11(2):475-84. PubMed ID: 22144665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and biological evaluation of a new class of geldanamycin derivatives as potent inhibitors of Hsp90.
    Le Brazidec JY; Kamal A; Busch D; Thao L; Zhang L; Timony G; Grecko R; Trent K; Lough R; Salazar T; Khan S; Burrows F; Boehm MF
    J Med Chem; 2004 Jul; 47(15):3865-73. PubMed ID: 15239664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity.
    Kasibhatla SR; Hong K; Biamonte MA; Busch DJ; Karjian PL; Sensintaffar JL; Kamal A; Lough RE; Brekken J; Lundgren K; Grecko R; Timony GA; Ran Y; Mansfield R; Fritz LC; Ulm E; Burrows FJ; Boehm MF
    J Med Chem; 2007 Jun; 50(12):2767-78. PubMed ID: 17488003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of cancer invasion and metastasis by targeting the molecular chaperone heat-shock protein 90.
    Koga F; Kihara K; Neckers L
    Anticancer Res; 2009 Mar; 29(3):797-807. PubMed ID: 19414312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HSP90 inhibitors for cancer therapy and overcoming drug resistance.
    Jhaveri K; Modi S
    Adv Pharmacol; 2012; 65():471-517. PubMed ID: 22959035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90.
    Sydor JR; Normant E; Pien CS; Porter JR; Ge J; Grenier L; Pak RH; Ali JA; Dembski MS; Hudak J; Patterson J; Penders C; Pink M; Read MA; Sang J; Woodward C; Zhang Y; Grayzel DS; Wright J; Barrett JA; Palombella VJ; Adams J; Tong JK
    Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17408-13. PubMed ID: 17090671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural and semisynthetic azaphilones as a new scaffold for Hsp90 inhibitors.
    Musso L; Dallavalle S; Merlini L; Bava A; Nasini G; Penco S; Giannini G; Giommarelli C; De Cesare A; Zuco V; Vesci L; Pisano C; Castorina M; Milazzo F; Cervoni ML; Dal Piaz F; De Tommasi N; Zunino F
    Bioorg Med Chem; 2010 Aug; 18(16):6031-43. PubMed ID: 20655237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tanespimycin: the opportunities and challenges of targeting heat shock protein 90.
    Erlichman C
    Expert Opin Investig Drugs; 2009 Jun; 18(6):861-8. PubMed ID: 19466875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The novel HSP90 inhibitor STA-1474 exhibits biologic activity against osteosarcoma cell lines.
    McCleese JK; Bear MD; Fossey SL; Mihalek RM; Foley KP; Ying W; Barsoum J; London CA
    Int J Cancer; 2009 Dec; 125(12):2792-801. PubMed ID: 19544563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small-molecule targeting of heat shock protein 90 chaperone function: rational identification of a new anticancer lead.
    Meli M; Pennati M; Curto M; Daidone MG; Plescia J; Toba S; Altieri DC; Zaffaroni N; Colombo G
    J Med Chem; 2006 Dec; 49(26):7721-30. PubMed ID: 17181154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blockade of Her2/neu binding to Hsp90 by emodin azide methyl anthraquinone derivative induces proteasomal degradation of Her2/neu.
    Yan YY; Zheng LS; Zhang X; Chen LK; Singh S; Wang F; Zhang JY; Liang YJ; Dai CL; Gu LQ; Zeng MS; Talele TT; Chen ZS; Fu LW
    Mol Pharm; 2011 Oct; 8(5):1687-97. PubMed ID: 21812426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90.
    Vilenchik M; Solit D; Basso A; Huezo H; Lucas B; He H; Rosen N; Spampinato C; Modrich P; Chiosis G
    Chem Biol; 2004 Jun; 11(6):787-97. PubMed ID: 15217612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress.
    Workman P; Burrows F; Neckers L; Rosen N
    Ann N Y Acad Sci; 2007 Oct; 1113():202-16. PubMed ID: 17513464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.